Clinical course of Merkel cell carcinoma: A DeCOG multicenter study of 1049 patients

Genitourinary Cancer

Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study)

Int J Cancer

Ciccarese C, Büttner T, Cerbone L, Zampiva I, Monteiro FSM, Basso U, Pichler M, Vitale MG, Fiala O, Roviello G, Kopp RM, Carrozza F, Pichler R, Grillone F, Calabuig EP, Zeppellini A, Küronya Z, Galli L, Facchini G, Sunela K, Mosca A, Molina-Cerrillo J, Spinelli GP, Ansari J, Scala A, Mollica V, Grande E, Buti S, Kanesvaran R, Zakopoulou R, Bamias A, Rizzo M, Massari F, Iacovelli R, Santoni M

doi: 10.1002/ijc.35141

Gastrointestinal Cancer

Activity of lenvatinib-based therapy in previously treated patients with metastatic renal cell carcinoma: A European multicenter study (LENVA-LAT)

Eur J Cancer

Gavira J, Auclin E, Rey-Cardenas M, Roy P, Tapia JC, Nay P, Vinceneux A, Lefort F, Nannini S, Randis AMDC, Naoun N, Escudier B, Borchiellini D, de Velasco G, Barthelemy P, Gross-Goupil M, Negrier S, Oudard S, Frazer RD, Albiges L, Flippot R

doi: 10.1016/j.ejca.2025.115389

Breast Cancer

Clinical and patient-reported outcomes after oncoplastic versus conventional breast conserving surgery-a longitudinal, multicenter cohort study

J Natl Cancer Inst

Bargon CA, Mink Van Der Molen DR, Young-Afat DA, Batenburg MCT, Van Dam IE, Baas IO, Ernst MF, Maarse W, Sier MF, Schoenmaeckers EJP, Burgmans JPJ, Bijlsma RM, Siesling S, Rakhorst HA, Mureau MA, Van Der Leij F, Doeksen A, Verkooijen HM, UMBRELLA Study Group

doi: 10.1093/jnci/djae310

Genitourinary Cancer

Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study

Lancet

Choueiri TK, Albiges L, Barthélémy P, Iacovelli R, Emambux S, Molina-Cerrillo J, Garmezy B, Barata P, Basu A, Bourlon MT, Moon H, Ratta R, McKay RR, Chehrazi-Raffle A, Hammers H, Heng DYC, Braendle E, Beckermann KE, McGregor BA, Motzer RJ

doi: 10.1016/S0140-6736(24)01758-6

Further Publications

Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: Analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare database

Eur J Cancer

Mortier L, Blom A, van Hille B, Samimi M, Luciani L, Cahuzac C, Robert C, Quereux G, Maubec E, Miotti H, Maillard C, Aubin F, Lenormand C, Solbes MN, Joly P, Kachaner I, Lebbé C, Dutriaux C, Saiag P

doi: 10.1016/j.ejca.2024.114261

Genitourinary Cancer

IMPACT OF 3D-PRINTED MODELS FOR SURGICAL PLANNING IN RENAL CELL CARCINOMA WITH VENOUS TUMOR THROMBUS. A RANDOMISED MULTICENTER CLINICAL TRIAL

J Urol

Rivero-Belenchón I, Congregado Ruíz CB, Gómez Ciriza G, Gómez Dos Santos V, Burgos Revilla FJ, Medina López RA

doi: 10.1097/JU.0000000000004425

Lung, Respiratory and Thoracic Cancer

Five-year efficacy and safety of pembrolizumab as first-line treatment in patients with non-small cell lung cancer with PD-L1 tumor proportion score ≥50 %: A multicenter observational study

Lung Cancer

Tambo Y, Sone T, Nishi K, Shibata K, Kita T, Araya T, Shirasaki H, Shimizu T, Yoneda T, Matsuoka H, Nanjo S, Koba H, Terada N, Ueda T, Nomura S, Murase Y, Yano S

doi: 10.1016/j.lungcan.2025.108422

Genitourinary Cancer

Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial

Int J Cancer

Grünwald V, McKay RR, Buchler T, Eto M, Park SH, Takagi T, Zanetta S, Keizman D, Suárez C, Négrier S, Lee JL, Santini D, Bedke J, Staehler M, Kollmannsberger C, Choueiri TK, Motzer RJ, Burgents JE, Xie R, Okpara CE, Powles T

doi: 10.1002/ijc.35288

Head and Neck Cancer

Clinical Benefit and Safety of Reduced Elective Dose in Definitive Radiotherapy for Head and Neck Squamous Cell Carcinoma: The UPGRADE-RT Multicenter Randomized Controlled Trial

J Clin Oncol

van den Bosch S, Doornaert PAH, Hoebers FJP, Kreike B, Vergeer MR, Zwijnenburg EM, Cox MC, Hannink G, Dijkema T, Kaanders JHAM, Dutch Head and Neck Society

doi: 10.1200/JCO-24-02194

Related content

Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study)

Activity of lenvatinib-based therapy in previously treated patients with metastatic renal cell carcinoma: A European multicenter study (LENVA-LAT)

Clinical and patient-reported outcomes after oncoplastic versus conventional breast conserving surgery-a longitudinal, multicenter cohort study

Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study

Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: Analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare database

IMPACT OF 3D-PRINTED MODELS FOR SURGICAL PLANNING IN RENAL CELL CARCINOMA WITH VENOUS TUMOR THROMBUS. A RANDOMISED MULTICENTER CLINICAL TRIAL

Five-year efficacy and safety of pembrolizumab as first-line treatment in patients with non-small cell lung cancer with PD-L1 tumor proportion score ≥50 %: A multicenter observational study

Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial

Clinical Benefit and Safety of Reduced Elective Dose in Definitive Radiotherapy for Head and Neck Squamous Cell Carcinoma: The UPGRADE-RT Multicenter Randomized Controlled Trial